Ivabradine Hydrochloride CAS 148849-67-6 Purity >99.5% (HPLC) API Factory

Short Description:

Chemical Name: Ivabradine Hydrochloride

Synonyms: Ivabradine HCl

CAS: 148849-67-6

Purity: >99.5% (HPLC)

Appearance: White to Off-White Crystalline Powder

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Ivabradine Hydrochloride Intermediates With High Purity
Ivabradine Hydrochloride CAS 148849-67-6
4,5-Dimethoxy-1-Cyanobenzocyclobutane CAS 35202-54-1
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride CAS 866783-13-3
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one CAS 73942-87-7
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one CAS 148870-57-9
3-(3-Chloropropyl)-7,8-dimethoxy-1H-3-benzazepin-2(3H)-one CAS 85175-59-3

Chemical Properties:

Chemical Name	Ivabradine Hydrochloride
Synonyms	Ivabradine HCl
CAS Number	148849-67-6
CAT Number	RF-PI1812
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C27H36N2O5·HCl
Molecular Weight	505.05
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Crystalline Powder
Identification	HPLC/UV Complies
Purity / Analysis Method	>99.5%
Loss on Drying	<1.00% (Dry it at 105℃ in an electric air blowing dryer till a constant weight)
Moisture Content	<1.00%
Residue on Ignition	<0.20%
Max Single Impurity	<0.50%
Total Impurities	<0.50%
Optical Isomer	<0.50%
Assay	>99.5%
Heavy Metals	<20ppm
Specific Rotation	+6.5° ~ +8.5° (on dried basis, 1% solution in DMSO)
Test Standard	Enterprise Standard
Usage	API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Ivabradine Hydrochloride (CAS: 148849-67-6), In an effort to develop angina agents without the unwanted negative inotropic and hypotensive effects associated with b-adrenergic blockers and calcium channel blockers, a new class of heart-rate reducing compounds that act specifically on the sinoatrial (SA) node has been explored. These bradycardic agents interact directly with the pacemaking cell of the SA node and the hyperpolarization- activated If the primary pacemaking current. Ivabradine has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, Ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease.